Read about how Crispr's robust pipeline for cardiovascular diseases holds blockbuster potential, with top-line results ...

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.

Wake up with Breakfast news in your inbox every market day. Sign Up For Free » Since November 2023, CRISPR Therapeutics has ...

This year saw several advancements across medicine, space technology, and AI that extend our knowledge in consequential ways.

Investors looking for stocks that can make dramatic gains can find some in the biopharmaceutical industry. Right now, there ...

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...